Melbourne – October 21, 2026 -- Telix will hold an in-person Research and Development Day in New York City on September 22, 2026, followed by a Capital Markets Day in Melbourne on November 4, 2026, giving institutional investors two scheduled windows into its strategy and pipeline.
Telix opens its New York R&D Day to institutional investors and analysts on September 22
The session runs from 8:30 a.m. to 12:30 p.m. EDT and will cover the company's therapeutic and precision medicine pipeline, along with scientific, clinical and strategic developments across the portfolio. Attendance is in person only and requires advance registration. Venue, agenda and presentation materials will go to registered attendees.
Five Telix executives will present alongside key opinion leaders
The presenters are Managing Director and Group CEO Dr. Christian Behrenbruch, Group Chief Medical Officer Dr. David N. Cade, CEO Therapeutics Richard Valeix, CEO Precision Medicine Kevin Richardson and Vice President Discovery Sciences Dr. Michael Wheatcroft. Key opinion leaders will also speak on the clinical and scientific opportunities.
Telix sets November 4 Capital Markets Day in Melbourne for strategy and financial targets
Management will update investors on strategy, growth outlook, financial targets and key business priorities at the Wednesday event. Telix will publish further details in a separate announcement.
Both events are restricted to qualified institutional investors and analysts.